Mohamed Al-Kazaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Al-Kazaz has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Paul C. Cremer
6 shared publicationsDouglas R. Johnston
Bluhm Cardiovascular Institute, Division of Cardiac Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
3 shared publications- Paul C. Cremer
Bluhm Cardiovascular Institute, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
3 shared publications Abigail S. Baldridge
Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
2 shared publicationsAkhil Narang
Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
2 shared publications- Alexis Attinoto
Northwestern University Feinberg School of Medicine
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Elsevier in JACC: Case Reports
Disseminated Nocardiosis With Perimyocardial Involvement
- 29 October 2026
- Published by Elsevier in JACC: Case Reports
Open AccessDisseminated Nocardiosis With Perimyocardial Involvement
- Open Access
- 30 July 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (1) , 61-63
State of the Art in Pericardial Disease: Webcast June 23 2026
This 58-minute webcast features a conversation on the “State of the Art in Pericardial Disease”—the focus of Issue 22.2 on the theme of pericardial disease. Led by the issue’s editor, the discussion engages the authors on emerging themes and lessons learned while researching and writing the articles. View the video at https://vimeo.com/1204339129/42dd65d78b.
- 30 July 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (1) , 61-63
Open AccessState of the Art in Pericardial Disease: Webcast June 23 2026
This 58-minute webcast features a conversation on the “State of the Art in Pericardial Disease”—the focus of Issue 22.2 on the theme of pericardial disease. Led by the issue’s editor, the discussion engages the authors on emerging themes and lessons learned while researching and writing the articles. View the video at https://vimeo.com/1204339129/42dd65d78b.
- 13 April 2026
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 34 (4) , 346-354
Ross procedure: Evidence for pulmonary autograft and early outcomes
Background: Renewed interest in the Ross procedure in young adults has been tempered by questions over safety and early outcomes. This paper examines our institution's 1-year outcomes of the Ross procedure. Methods: From November 2019 to February 2025, 136 consecutive adult patients underwent a Ross procedure at an urban tertiary center. The first 50 patients had follow-up beyond 1 year and constitute the study group of this case series. Results: Median age was 41 years (IQR: 30, 47). The majority were male ( n = 34, 68%). The most common indication for surgery was aortic stenosis with or without aortic regurgitation (AR) ( n = 34, 68%), followed by pure AR ( n = 14, 28%), then aortic aneurysm with valve dysfunction ( n = 2, 4%). Valve morphology was bicuspid in 22 (44%) patients, unicuspid in 21 (42%), and tricuspid in 5 (10%). Primary etiology was congenital in 42 (84%) patients, degenerative in 2 (4%), failed mechanical valve in 2 (4%), healed endocarditis in 1 (2%), rheumatic disease in 1 (2%), radiation-induced in 1 (2%), and unknown in 1 (2%). Redo sternotomy was performed in 2 (4%) patients, ascending aorta replacement in 43 (86%), hemiarch replacement in 22 (44%), and external aortic annuloplasty ring in 23 (46%). In-hospital and 30-day mortality was 0%, with 2 (4%) permanent strokes post-operatively but with no or minimal residual deficits. There was 1 mortality at 1.1 years, 1 autograft re-intervention at 1.8 years, 1 autograft re-intervention at 4.1 years, and 1 homograft re-intervention at 2.7 years. Conclusion: This paper demonstrates early safety of the Ross procedure for adults. More longitudinal data is needed to determine long-term efficacy and durability.
- 13 April 2026
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 34 (4) , 346-354
Ross procedure: Evidence for pulmonary autograft and early outcomes
Background: Renewed interest in the Ross procedure in young adults has been tempered by questions over safety and early outcomes. This paper examines our institution's 1-year outcomes of the Ross procedure. Methods: From November 2019 to February 2025, 136 consecutive adult patients underwent a Ross procedure at an urban tertiary center. The first 50 patients had follow-up beyond 1 year and constitute the study group of this case series. Results: Median age was 41 years (IQR: 30, 47). The majority were male ( n = 34, 68%). The most common indication for surgery was aortic stenosis with or without aortic regurgitation (AR) ( n = 34, 68%), followed by pure AR ( n = 14, 28%), then aortic aneurysm with valve dysfunction ( n = 2, 4%). Valve morphology was bicuspid in 22 (44%) patients, unicuspid in 21 (42%), and tricuspid in 5 (10%). Primary etiology was congenital in 42 (84%) patients, degenerative in 2 (4%), failed mechanical valve in 2 (4%), healed endocarditis in 1 (2%), rheumatic disease in 1 (2%), radiation-induced in 1 (2%), and unknown in 1 (2%). Redo sternotomy was performed in 2 (4%) patients, ascending aorta replacement in 43 (86%), hemiarch replacement in 22 (44%), and external aortic annuloplasty ring in 23 (46%). In-hospital and 30-day mortality was 0%, with 2 (4%) permanent strokes post-operatively but with no or minimal residual deficits. There was 1 mortality at 1.1 years, 1 autograft re-intervention at 1.8 years, 1 autograft re-intervention at 4.1 years, and 1 homograft re-intervention at 2.7 years. Conclusion: This paper demonstrates early safety of the Ross procedure for adults. More longitudinal data is needed to determine long-term efficacy and durability.
- Open Access
- 10 March 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (2) , 97-109
Perioperative and Surgical Management of Constrictive Pericarditis
Constrictive pericarditis represents a form of severe diastolic heart failure characterized by impaired diastolic filling due to a rigid, noncompliant pericardium. Surgical pericardiectomy is the definitive treatment for chronic or refractory subacute constrictive pericarditis; however, outcomes vary widely depending on disease etiology, chronicity, myocardial involvement, end-organ dysfunction, and surgical technique. This review summarizes contemporary best practices for the surgical management of constrictive pericarditis, with emphasis on patient selection, timing of intervention, operative approach, and perioperative considerations. Accurate differentiation between inflammatory, transient constrictive phenotypes and irreversible fibrotic disease is central to therapeutic decision-making. Etiology-based risk stratification, assessment of hepatic and renal dysfunction, and careful evaluation of myocardial involvement provide critical prognostic information. Multimodality imaging plays a central role in diagnosis, surgical planning, and identification of patients most likely to benefit from intervention. Radical pericardiectomy is associated with superior functional recovery compared with partial resection, whereas radiation-associated disease, mixed constrictive–restrictive physiology, and advanced end-organ dysfunction are consistently linked to worse outcomes. High-volume centers of excellence in pericardial disease are critical in optimizing results after radical pericardiectomy.
- 10 March 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (2) , 97-109
Open AccessPerioperative and Surgical Management of Constrictive Pericarditis
Constrictive pericarditis represents a form of severe diastolic heart failure characterized by impaired diastolic filling due to a rigid, noncompliant pericardium. Surgical pericardiectomy is the definitive treatment for chronic or refractory subacute constrictive pericarditis; however, outcomes vary widely depending on disease etiology, chronicity, myocardial involvement, end-organ dysfunction, and surgical technique. This review summarizes contemporary best practices for the surgical management of constrictive pericarditis, with emphasis on patient selection, timing of intervention, operative approach, and perioperative considerations. Accurate differentiation between inflammatory, transient constrictive phenotypes and irreversible fibrotic disease is central to therapeutic decision-making. Etiology-based risk stratification, assessment of hepatic and renal dysfunction, and careful evaluation of myocardial involvement provide critical prognostic information. Multimodality imaging plays a central role in diagnosis, surgical planning, and identification of patients most likely to benefit from intervention. Radical pericardiectomy is associated with superior functional recovery compared with partial resection, whereas radiation-associated disease, mixed constrictive–restrictive physiology, and advanced end-organ dysfunction are consistently linked to worse outcomes. High-volume centers of excellence in pericardial disease are critical in optimizing results after radical pericardiectomy.
- Open Access
- 10 March 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (2) , 85-96
Constrictive Pericarditis and Effusive Constrictive Pericarditis: Is There a Role for Medical Therapy?
Constrictive pericarditis (CP) represents a spectrum of pericardial diseases characterized by impaired ventricular filling due to a noncompliant pericardium. Within this continuum, effusive constrictive pericarditis (ECP) and transient constrictive pericarditis are characterized by active inflammation. ECP combines pericardial effusion and constrictive physiology, whereas transient constrictive pericarditis is characterized by resolution, often after anti-inflammatory therapy. These conditions often result from idiopathic, post-surgical, autoimmune, or tuberculous causes and may progress from acute inflammation to chronic fibrosis and calcification, termed chronic constrictive pericarditis. Multimodality imaging, including echocardiography, cardiac magnetic resonance imaging, and cardiac computed tomography, plays a key role in establishing the diagnosis, assessing inflammation, and guiding treatment. In patients with active pericardial inflammation, increasing evidence and practice supports the early and combined initiation of anti-inflammatory therapy including nonsteroidal agents, colchicine, corticosteroids, and interleukin-1 inhibitors to reverse constrictive pathophysiology.
- 10 March 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (2) , 85-96
Open AccessConstrictive Pericarditis and Effusive Constrictive Pericarditis: Is There a Role for Medical Therapy?
Constrictive pericarditis (CP) represents a spectrum of pericardial diseases characterized by impaired ventricular filling due to a noncompliant pericardium. Within this continuum, effusive constrictive pericarditis (ECP) and transient constrictive pericarditis are characterized by active inflammation. ECP combines pericardial effusion and constrictive physiology, whereas transient constrictive pericarditis is characterized by resolution, often after anti-inflammatory therapy. These conditions often result from idiopathic, post-surgical, autoimmune, or tuberculous causes and may progress from acute inflammation to chronic fibrosis and calcification, termed chronic constrictive pericarditis. Multimodality imaging, including echocardiography, cardiac magnetic resonance imaging, and cardiac computed tomography, plays a key role in establishing the diagnosis, assessing inflammation, and guiding treatment. In patients with active pericardial inflammation, increasing evidence and practice supports the early and combined initiation of anti-inflammatory therapy including nonsteroidal agents, colchicine, corticosteroids, and interleukin-1 inhibitors to reverse constrictive pathophysiology.
- Open Access
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70457
Postoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Postoperative atrial arrhythmia (POAA) is common after lung transplant, but data on its implications and management are limited. This study assessed POAA incidence and timing, its association with mortality and rehospitalizations, and outcomes related to postoperative beta‐blocker use. Methods: We retrospectively studied 233 adult lung transplant patients at Northwestern Memorial Hospital (2014–2024) without prior atrial arrhythmia. POAA, defined as atrial fibrillation or flutter, was confirmed by ECG or ambulatory monitoring. Multivariable logistic and Cox regression models evaluated predictors and outcomes, adjusting for covariates. Results: POAA occurred in 69/233 patients (29.6%) and was associated with higher mortality (HR3.09, 95%CI [1.57–6.08]). Among these, 18/69 (26.1%) developed POAA after the index hospitalization at median 216 days post‐transplant, also associated with higher mortality (HR4.37, 95%CI [1.90–10.06]). Additionally, 10/69 (14.5%) required emergency visits or hospitalization specifically for arrhythmia management, and 66.6% underwent additional rhythm control (2.9% cardioversion, 46.4% anti‐arrhythmic drug, 17.4% both). Postoperative beta‐blocker use was associated with 73% less POAA (HR0.27, 95%CI [0.09–0.80]). Conclusion: POAA was common and clinically significant after lung transplant, associated with substantially higher adjusted mortality even when occurring after index hospitalization. We report for the first time that POAA was frequently associated with emergency visits or rehospitalization for arrhythmia, highlighting its clinical burden well beyond the perioperative period. Postoperative beta‐blocker use was associated with markedly less POAA, a novel finding suggesting a potential prophylactic role. Overall, these findings challenge the traditional view of POAA as benign and highlight the need for tailored, evidence‐based guidelines in this high‐risk population.
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70457
Open AccessPostoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes
Background: Postoperative atrial arrhythmia (POAA) is common after lung transplant, but data on its implications and management are limited. This study assessed POAA incidence and timing, its association with mortality and rehospitalizations, and outcomes related to postoperative beta‐blocker use. Methods: We retrospectively studied 233 adult lung transplant patients at Northwestern Memorial Hospital (2014–2024) without prior atrial arrhythmia. POAA, defined as atrial fibrillation or flutter, was confirmed by ECG or ambulatory monitoring. Multivariable logistic and Cox regression models evaluated predictors and outcomes, adjusting for covariates. Results: POAA occurred in 69/233 patients (29.6%) and was associated with higher mortality (HR3.09, 95%CI [1.57–6.08]). Among these, 18/69 (26.1%) developed POAA after the index hospitalization at median 216 days post‐transplant, also associated with higher mortality (HR4.37, 95%CI [1.90–10.06]). Additionally, 10/69 (14.5%) required emergency visits or hospitalization specifically for arrhythmia management, and 66.6% underwent additional rhythm control (2.9% cardioversion, 46.4% anti‐arrhythmic drug, 17.4% both). Postoperative beta‐blocker use was associated with 73% less POAA (HR0.27, 95%CI [0.09–0.80]). Conclusion: POAA was common and clinically significant after lung transplant, associated with substantially higher adjusted mortality even when occurring after index hospitalization. We report for the first time that POAA was frequently associated with emergency visits or rehospitalization for arrhythmia, highlighting its clinical burden well beyond the perioperative period. Postoperative beta‐blocker use was associated with markedly less POAA, a novel finding suggesting a potential prophylactic role. Overall, these findings challenge the traditional view of POAA as benign and highlight the need for tailored, evidence‐based guidelines in this high‐risk population.
- Open Access
- 21 January 2026
- Published by Springer Nature in Current Cardiology Reports
- Vol. 28 (1) , 13
Contemporary Assessment and Management of Effusive-Constrictive Pericarditis
Purpose of Review: Effusive-constrictive pericarditis (ECP) is a complex clinical condition that combines features of pericardial effusion/tamponade and constrictive pericarditis. The classic hemodynamic definition is persistent elevation of right atrial pressure despite drainage of a pericardial effusion. This review summarizes recent data on its epidemiology, pathophysiology, diagnosis, and management. Recent Findings: Prevalence varies from 2.4% to 14.8% depending on diagnostic criteria and etiology, reaching up to 50% in tuberculous pericarditis in endemic regions. Common causes include idiopathic, infectious (particularly tuberculous and bacterial), malignant, and post-surgical etiologies. While invasive hemodynamic assessment remains the reference standard, echocardiography is now the primary diagnostic tool, enabling recognition of constrictive physiology before and after pericardiocentesis. Cardiac magnetic resonance adds complementary information on pericardial thickness, inflammation, and potential for reversibility, aiding therapeutic decisions. Inflammatory ECP frequently resolves with medical therapy (NSAIDs, colchicine, corticosteroids, or IL-1 inhibitors) while tuberculous cases require antimicrobial therapy with corticosteroids in selected patients. Summary: ECP is a heterogeneous condition with variable clinical trajectories. Early identification through multimodality imaging is essential to guide therapy, target reversible inflammation, and prevent chronic constriction. Most inflammatory cases respond to anti-inflammatory treatment, whereas pericardiectomy is reserved for persistent, irreversible constrictive physiology despite optimal medical therapy.
- 21 January 2026
- Published by Springer Nature in Current Cardiology Reports
- Vol. 28 (1) , 13
Open AccessContemporary Assessment and Management of Effusive-Constrictive Pericarditis
Purpose of Review: Effusive-constrictive pericarditis (ECP) is a complex clinical condition that combines features of pericardial effusion/tamponade and constrictive pericarditis. The classic hemodynamic definition is persistent elevation of right atrial pressure despite drainage of a pericardial effusion. This review summarizes recent data on its epidemiology, pathophysiology, diagnosis, and management. Recent Findings: Prevalence varies from 2.4% to 14.8% depending on diagnostic criteria and etiology, reaching up to 50% in tuberculous pericarditis in endemic regions. Common causes include idiopathic, infectious (particularly tuberculous and bacterial), malignant, and post-surgical etiologies. While invasive hemodynamic assessment remains the reference standard, echocardiography is now the primary diagnostic tool, enabling recognition of constrictive physiology before and after pericardiocentesis. Cardiac magnetic resonance adds complementary information on pericardial thickness, inflammation, and potential for reversibility, aiding therapeutic decisions. Inflammatory ECP frequently resolves with medical therapy (NSAIDs, colchicine, corticosteroids, or IL-1 inhibitors) while tuberculous cases require antimicrobial therapy with corticosteroids in selected patients. Summary: ECP is a heterogeneous condition with variable clinical trajectories. Early identification through multimodality imaging is essential to guide therapy, target reversible inflammation, and prevent chronic constriction. Most inflammatory cases respond to anti-inflammatory treatment, whereas pericardiectomy is reserved for persistent, irreversible constrictive physiology despite optimal medical therapy.
- Open Access
- 10 December 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (40) , 105862
Multimodality Imaging of Intracardiac Lesions in a Lung Transplant Patient
- 10 December 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (40) , 105862
Open AccessMultimodality Imaging of Intracardiac Lesions in a Lung Transplant Patient
- Open Access
- 28 July 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (14) , 1762-1772
Outcomes of Entrapped Right Ventricular Pacing or Defibrillator Leads Following Transcatheter Tricuspid Valve Replacement
- 28 July 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (14) , 1762-1772
Open AccessOutcomes of Entrapped Right Ventricular Pacing or Defibrillator Leads Following Transcatheter Tricuspid Valve Replacement
- Open Access
- 15 July 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (18)
Rare Presentation of a Primary Cardiac Mass
- 15 July 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (18)
Open AccessRare Presentation of a Primary Cardiac Mass